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RESEARCH ARTICLE
Abrogation of transforming growth factor-β-
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transgenic mice by the second generation
tyrosine kinase inhibitor SKI-606 (Bosutinib)
Peter J. Wermuth, Sergio A. Jimenez*
Jefferson Institute of Molecular Medicine and Scleroderma Center, Thomas Jefferson University,
Philadelphia, PA, United States of America
* sergio.jimenez@jefferson.edu
Abstract
Transforming growth factor-β (TGF-β) plays a crucial role in the pathogenesis of Systemic
Sclerosis (SSc) and other fibrotic disorders. TGF-β-mediated c-Abl and Src kinase activa-
tion induces strong profibrotic cascade signaling. The purpose of this study was to test in
vivo the antifibrotic activity of Bosutinib (SKI-606), a second generation c-Abl and Src kinase
inhibitor, on TGF-β induced cutaneous and pulmonary fibrosis. For this purpose, we
employed the TBRIcaCol1a2Cre transgenic mice expressing an inducible constitutively
active TGF-β receptor 1 constitutively activated by Col1a promoter-mediated Cre recombi-
nase. The mice were treated parenterally with 2.5, 5.0 or 10.0 mg/kg/day of Bosutinib for 42
days. Skin and lungs from control and Bosutinib-treated mice (n = 6 per group) were
assessed by histopathology, measurement of tissue hydroxyproline content, PCR analysis
of tissue fibrosis associated gene expression, and evidence of myofibroblast activation.
Mice with constitutive TGF-β-1 signaling displayed severe cutaneous and pulmonary fibro-
sis. Bosutinib administration decreased collagen deposition and hydroxyproline content in
the dermis and lungs in a dose-dependent manner. Bosutinib also reversed the marked
increase in profibrotic and myofibroblast activation-associated gene expression. These
results demonstrate that constitutive TGF-β-1-signaling-induced cutaneous and pulmonary
fibrosis were abrogated in a dose-related manner following parenteral administration of the
c-Abl and Src tyrosine kinase inhibitor, Bosutinib. These results indicate that Bosutinib may
be a potential therapeutic agent for tissue fibrosis in SSc and other fibroproliferative
disorders.
Introduction
Fibrotic disorders including Systemic Sclerosis (SSc) are characterized by exaggerated local or
systemic pathologic extracellular matrix (ECM) and fibrous tissue accumulation. These disor-
ders are responsible for high morbidity and mortality worldwide [1–7]. Despite distinct and
varied etiologies of fibrotic disorders and a remarkable heterogeneity in their clinical
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manifestations several common molecular mechanisms and signaling pathways regulate their
pathogenesis [8–11]. A hallmark of these diseases is the increased expression, production and
tissue accumulation of ECM proteins including the fibrillar types I, III and VI collagens and
fibronectin, disrupting the normal architecture of the affected organs resulting in their dys-
function and eventual failure. The chronic and progressive nature of fibrotic diseases, the large
array of affected organs, and the lack of effective disease modifying therapeutics render them a
challenge to efficient medical management [1–3,8]. The mortality attributed to fibrotic dis-
eases in Western countries may be as high as 45% or even higher in less developed and devel-
oping nations [1–3,8].
The fibroproliferative phenotype is largely mediated by activated myofibroblasts [12–15],
the cells responsible for the increased production of various ECM macromolecules, including
fibrillar type l, type lll, and type VI collagens and fibronectin, and a concomitant reduction of
ECM-degrading matrix metalloproteinase activity. Activated myofibroblasts are characterized
by the expression and production of α-smooth muscle actin (α-SMA), a protein that confers
these cells a contractile phenotype allowing their migration and the extension of tissue damage.
Although several cytokines and growth factors, such as transforming growth factor β (TGF-β),
platelet-derived growth factor (PDGF), and connective tissue growth factor, play important
roles in tissue fibrosis, the molecular pathways responsible are not completely understood
[9,16–19].
SSc is a systemic autoimmune disease characterized by exaggerated and often progressive
skin and multiple internal organ fibrosis leading to severe organ damage and high mortality
[4,5]. Although its etiology is unknown, TGF-β signaling is crucial in SSc pathogenesis
[5,9,17,18,20], rendering it an attractive target for SSc-disease-modifying therapies. In normal
cells, TGF-β isoforms initiate signaling following binding to membrane-associated serine/thre-
onine protein kinase TGF-β receptors [21]. The TGF-β type I and type II receptors (TBRI and
TBRII, respectively) are present as homodimers in the membrane. Binding of the dimerized
TGF-β ligand to the TBRII homodimer allows for the recruitment of the TBRI (also known as
ALK5) homodimer and triggers the formation of a mature heterotetramer receptor complex,
allowing the constitutively active TBRII kinase to autophosphorylate and then transphosphor-
ylate the TBRI kinase [22]. Signaling by this activated receptor complex can then proceed
through a canonical pathway or by one or more non-canonical pathways. In canonical TGF-β
signaling, the C-terminal regions of the SMAD2 and SMAD3 proteins [23,24] are phosphory-
lated by the activated TBRI [25], allowing association with the co-mediator SMAD4 and
nuclear accumulation of the SMAD2/3 complex where it can then regulate transcription of
downstream genes [26]. Several non-canonical signaling pathways that do not depend on
SMAD phosphorylation and nuclear accumulation have been described and include the mito-
gen activated protein kinases (MAPKs) ERK, p38 and JNK, PI3K/Akt and Rho GTPase path-
ways [27–29]. This diversity of signaling pathways involved mediate the pleiotropic
downstream effects of TGF-β on cellular and molecular processes. Upregulation of TGF-β and
its receptors [30–32] and of the TGF-β-regulated gene CCN2 or connective tissue growth fac-
tor (CTGF) also known as CCN2 has been reported in SSc fibroblasts and tissue samples [33],
although the increased expression of CCN2/CTGF is Smad3-independent but Smad1-depen-
dent [34,35]. Investigation of the role of TGF-β signaling in the induction of a fibrotic pheno-
type in SSc fibroblasts using small molecule inhibitors, antibodies, siRNA directed against the
TGF-β receptors or SMADs as well as knockout mouse models has indicated the involvement
and dysregulation of both canonical [36–38] and non-canonical [39–41] pathways.
Despite these studies implicating dysregulation of TGF-β signaling in mediating the induc-
tion of fibrosis in SSc, therapeutic approaches aimed at inhibition of TGF-β signaling have not
been successful, largely owing to serious side effects caused by inhibition of the multiple
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pleiotropic effects of TGF-β as well as by crosstalk with numerous associated molecular signal-
ing pathways. For example, metelimumab (CAT-192), a monoclonal antibody against TGF-β1,
induced significant morbidity and mortality in a study of 45 patients with early-stage diffuse
cutaneous SSc. CAT-192 also showed no evidence of efficacy compared to placebo as evaluated
by changes in the modified Rodnan skin thickness score (MRSS), assessment of organ-based
involvement and measurement of clinical biochemical parameters such as serum levels of solu-
ble interleukin-2 receptor, collagen propeptides or of tissue levels of mRNA for procollagens I
and III or for TGF-β1 [42]. A randomized, double-blind, multicenter, placebo-controlled trial
utilizing CAT-152, a monoclonal antibody directed against TGF-β2, to evaluate its effect in
preventing the progression of fibrosis in patients undergoing an initial trabeculectomy for pri-
mary open-angle or chronic angle-closure glaucoma demonstrated no statistically significant
improvement compared to the placebo group over the course of the 12 month study [43]. In
contrast, fresolimumab, an antibody that targets all three TGF-β isoforms improved clinical
symptoms in a small proof-of-concept study of 15 SSc patients for 24 weeks [44]. Clinical
improvement was measured by evaluating changes in the MRSS score as well as changes in the
expression levels of the TGF-β-regulated biomarker genes thrombospondin-1 (THBS1) and
cartilage oligomeric protein (COMP).
Modifying the activity of various tyrosine kinases to target tissue fibrosis has been intensely
investigated [45–48]. Recently much interest has focused on the non-receptor Src kinases
owing to their participation in various signal transduction pathways regulating important cel-
lular processes including cell migration, apoptosis, cytoskeletal rearrangements, and cellular
proliferation and differentiation [49–52]. Several profibrotic growth factors including PDGF
and TGF-β activate Src kinase signaling by stimulating the phosphorylation of a tyrosine resi-
due in its catalytic region [51,52]. Furthermore, several molecules involved in TGF-β-induced
conversion of quiescent fibroblasts to activated myofibroblasts, such as focal adhesion kinase
(FAK), hydrogen peroxide inducible gene 5 (HIC-5), myocardin-related transcription factor
(MRTFA), and extracellular signal-regulated kinase 1/2 (ERK1), are regulated by Src and con-
tribute to the persistent profibrotic phenotype of SSc fibroblasts [53–59]. Therefore, Src kinase
inhibitors represent potentially novel and effective agents for treating fibrotic diseases.
Imatinib mesylate, a small-molecule tyrosine kinase inhibitor that targets Abl kinase activity
associated with the Bcr-Abl translocation found in chronic myelogenous leukemia (CML) also
blocks the activity of PDGFR, c-kit and c-fms (also known as colony stimulating factor 1
receptor or CSF1R). Treatment of SSc fibroblasts in vitro with imatinib inhibited the expres-
sion and production of several extracellular matrix components, including both type I collagen
alpha 1 (Col1a1), and alpha 2 Col1a2 chains as well as fibronectin-1 in a dose-dependent man-
ner and did not induce compensatory changes in the expression of matrix metalloproteinases
or of tissue inhibitors of matrix metalloproteinases [60,61]. These effects were confirmed in
vivo utilizing several animal models of systemic and tissue-specific fibrosis [60–64]. Further-
more, several small case series and case reports in SSc patients have shown improvement [65–
67], and one study reported that imatinib induced improvement in two patients with Nephro-
genic Systemic Fibrosis [68]. A randomized, placebo-controlled, double-blind trial examining
the effect of imatinib treatment over 96 weeks in patients with idiopathic pulmonary fibrosis
found imatinib treatment was well tolerated in these patients, although there was no effect on
either survival or of clinical outcomes measures such as forced vital capacity, or other lung
functions compared to the placebo group [69]. Second generation Abl inhibitors dasatinib and
nilotinib have demonstrated similar anti-fibrotic effects in an animal model of fibrosis [70].
Bosutinib, or SKI-606 is a third-generation tyrosine kinase inhibitor developed to inhibit
the BCR-Abl kinase responsible for Philadelphia chromosome positive CML. Bosutinib was
approved for treating chronic-, accelerated-, and blast-phase CML in patients resistant to
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Imatinib [71,72]. Although BCR-Abl is not involved in tissue fibrosis pathogenesis, Bosutinib
also inhibits the profibrotic c-Abl tyrosine kinase [73]. Bosutinib is also a potent Src kinase
inhibitor, however, the kinase inhibitory effects of Bosutinib do not perturb the PDGF signal-
ing pathway whose inhibition has been associated with severe side effects [74,75]. Indeed,
Bosutinib therapy induces substantially less fluid retention and cardiac conduction problems
compared with the first- and second-generation Src inhibitors Imatinib and Nilotinib, respec-
tively [76].
The effects of Bosutinib on the expression and production of pro-fibrotic molecules and on
the phenotypic transition of normal to activated myofibroblasts in dermal fibroblasts from SSc
patients were examined previously in vitro [77]. The results showed a potent and dose-depen-
dent inhibition of the increased gene expression of the profibrotic extracellular matrix proteins
COL1A2, COL3A1, FN1 and of the profibrotic growth factor CTGF/CCN2 and a marked
reduction of the increased production of the corresponding proteins in cultured dermal SSc
fibroblasts. Bosutinib also abrogated the conversion of normal dermal fibroblasts into activated
myofibroblasts as assessed by cellular levels of the myofibroblast marker α-SMA and reversed
the abnormal profibrotic phenotype of dermal fibroblasts cultured from patients with diffuse
SSc of recent onset [77]. Additionally, the highest concentration of Bosutinib examined (5
nM) mediated a 30% reduction in the amount of secreted collagen in SSc fibroblasts and a
nearly 40% reduction in the amount of collagen and fibronectin in SSc fibroblast lysates. The
studies described here are, to our knowledge, the first demonstration of potent antifibrotic
effects of Bosutinib in vivo in a highly relevant transgenic mouse model of tissue fibrosis
[78,79].
Methods
Experimental animals
All animal studies were reviewed and approved by the Institutional Animal Care and Use
Committee at Thomas Jefferson University. Mice overexpressing a constitutively-activated
fibroblast-specific form of the TGF-β receptor I under the control of the Col1α2 collagen gene
promoter requiring tamoxifen for activation (TBRIca Col1a2-Cre) were employed in these
studies. These mice develop extensive cutaneous and lung fibrosis following TBRIca expression
in fibroblasts. TBRIca activation in these mice (provided by Dr. Benoit de Crumbrugghe)
[78,79]was achieved by intraperitoneal injection of 1 mg 4-OH tamoxifen daily for 5 days.
Only male mice were used given the remarkable gender differences in tissue fibrosis extent
and severity [80,81]. Following the initial tamoxifen injection, mice were divided into 4 groups
of 6 mice each and anesthetized with ketamine and xylazine followed by implantation of sub-
dermal Alzet osmotic pumps (model #2006) containing either saline (control mice) or 2.5, 5.0
or 10.0 mg/kg/day Bosutinib dispensing their contents at a constant rate of 0.25 μl/hr for 42
days. Lidocaine was administered subcutaneously adjacent to the incision site pre- and post-
operatively to minimize discomfort of the animals.
Histopathological tissue analysis and determination of tissue
hydroxyproline content
All mice were sacrificed at 42 days post pump implantation by CO2 asphyxiation and full
thickness skin samples were excised from the dorsum of each mouse and both lungs were iso-
lated. A portion of each tissue sample was fixed in 10% buffered formalin, embedded in paraf-
fin, and sections (5 μM thickness) were obtained and stained with hematoxylin and eosin or
with Masson’s trichrome.
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A portion of the skin and lung samples isolated from each animal was weighed immediately
following removal and acid-hydrolyzed overnight in 6N HCl at 107˚C. The hydrolysates were
assayed for their total hydroxyproline content as described [82,83]. The hydroxyproline con-
tent per mg wet tissue was determined by comparing the absorbance of each sample to a stan-
dard curve generated by assay of known amounts of 4-hydroxyproline. The hydroxyproline
values were converted to amounts of collagen using a conversion factor of 7.5 since hydroxy-
proline represents ~13.5% of the amino acid content of collagen [82].
RNA isolation and real-time polymerase chain reaction (RT-PCR)
Total RNA was extracted from skin and lung samples using Trizol and first-strand cDNA was
generated using SuperScript II Reverse Transcriptase (Invitrogen). Transcript levels of genes
encoding ECM macromolecules, myofibroblast differentiation and activation proteins, and
downstream TGF-β transcription factors were determined using SYBR Green real-time PCR
as previously described [84,85]. Primers were designed using Primer Quest (Integrated DNA
Technologies) and were validated for specificity. The sequences of the primers employed are
shown in Table 1. Differences in mRNA transcript levels in each PCR were corrected for 18S
RNA endogenous control transcript levels; levels in control mice were set at 100% and all
other values were expressed as multiples of the control values.
Statistical analyses
Data are expressed as mean ± standard deviation. Statistical significance of changes in
gene expression levels or in hydroxyproline content was evaluated by Student’s t-test with
a p value <0.05 deemed significant.
Results
Effects of Bosutinib on dermal fibrosis induced by constitutive TGF-β
signaling in TBRIca-Col1a2-Cre mice
The antifibrotic effects of Bosutinib in vivo were examined employing a highly relevant murine
model of tissue fibrosis induced by TGF-β overexpression in fibroblasts [80,81]. These mice,
carrying a floxed constitutively active TGF-β receptor (TBRI) allele activated by tamoxifen-
Table 1. Sequence of primers used for RT-PCR.
Gene Forward Primer (5’-3’) Reverse Primer (5’-3’)
18S ACCAGAGCGGAAAGCATTTGCCA TCGGCATCGTTTATGGTCGGAA
Acta2/
Sma
GACTCTCTTCCAGCCATCTTTC GACAGGACGTTGTTAGCATAGA
Col1a1 GCATGGCCAAGAAGACATCG TCCACGTCTCAGCATTGGG
Col3a1 AGCTTTGTGCAAAGTGGAACCTGG CAAGGTGGCTGCATCCCAATTCAT
Comp CGTGGGCTGGAAGGATAAA TACTAGCTCAGGACCCTCATAG
Ctgf ACTATGATGCGAGCCAACTG CTCCAGTCTGCAGAAGGTATTG
Erk1 CTGGCTTTCTGACGGAGTATG AGACCAGATGTCGATGGATTTG
Erk2 GTTGGTACAGAGCTCCAGAAA GGAAGATAGGCCTGTTGGATAG
Fn1 TCCAGGACAACAGCATCAGTGTCA CCACAGTGGGTTGCAAACCTTCAA
Fn-Eda TAAAGGACTGGCATTCACTGA GTGCAAGGCAACCACACTGAC
Hic5 GGAGGACCAATCTGAAGACAAG TCAGTCTATCCAGTTCCTGAGT
Tgfb1 AAAGGCCACTGGGTAAAGGAGAGT AAAGGCCACTGGGTAAAGGAGAGT
Tgfbr1 ATGTCCGCGTCCCACTA CCAGAGTCTCTAGACTGTCCAT
https://doi.org/10.1371/journal.pone.0196559.t001
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induced Cre recombinase expression under control of the fibroblast-specific Col1A2 promoter
develop extensive cutaneous and lung fibrosis [78,79]. The mice employed here may be a more
pathophysiologically relevant tissue fibrosis model than the more widely employed bleomycin-
induced fibrosis model [86,87]. Masson’s trichrome-stained full thickness skin sections from
saline-injected control mice displayed normal tissue architecture and collagen staining (Fig
1A), whereas tamoxifen-activated TBRIca-Col1a2-Cre mice skin demonstrated striking fibrosis
with a marked increase in dermal thickness, accumulation of densely packed and irregularly
arranged collagen bundles, and a marked increase in ECM collagen in the dermis and subder-
mal tissues (Fig 1A). The hypodermis also showed marked collagen infiltration and decreased
overall adipose layer thickness. Abnormal collagen deposition occurred between individual
muscle fibers of the panniculus carnosus in tamoxifen-injected animals compared with control
mice. The epidermis did not differ between the control and tamoxifen-activated groups.
Tamoxifen-injected TBRIca-Col1a2-Cre mice treated with Bosutinib dispensed continu-
ously for 42 days employing subdermal osmotic pumps displayed a dose-dependent decrease
in dermal fibrosis compared with saline control TBRIca-Col1a2-Cre animals injected with
tamoxifen (Fig 1A). Even in mice receiving only 2.5 mg/kg/day of Bosutinib dermal thickness
and collagen bundle accumulation were noticeably decreased. These changes were more evi-
dent in mice treated with 5 mg/kg/day Bosutinib with the maximal effect observed in 10 mg/
kg/day Bosutinib-treated mice that displayed near normal levels of collagen and ECM deposi-
tion in the dermis and essentially normal hypodermal tissue and subdermal muscle layers.
Effects of Bosutinib on pulmonary fibrosis induced by constitutive TGF-β
signaling in TBRIca-Col1a2-Cre mice
Trichrome staining of the lungs from untreated tamoxifen-injected animals displayed severe
alterations of the normal alveolar architecture with extensive areas of fibrosis causing alveolar
septae thickening and fibrotic parenchymal consolidation, compared to mock-injected (no
tamoxifen) control mice (Fig 1B). Marked interstitial, perivascular and peribronchiolar colla-
gen accumulation was present (Fig 1B). In contrast, tamoxifen-injected Bosutinib-treated
TBRIca-Col1a2-Cre mice (Fig 1B) displayed a dose-dependent decrease in pulmonary fibrosis
and alveolar/parenchymal abnormalities compared with animals injected with tamoxifen
alone. Even in mice receiving only 2.5 mg/kg/day of Bosutinib lung tissue consolidation and
collagen deposition were markedly decreased with substantially less alveolar architecture dis-
tortion. These improvements were more evident in 10 mg/kg/day Bosutinib-treated mice
which displayed near normal levels of collagen and ECM deposition and essentially complete
abrogation of tissue consolidation.
Hydroxyproline content in tissues of TBRIca-Col1a2-Cre mice
Hydroxyproline content of dorsal skin and lung samples was measured to assess quantitatively
the extent of collagen deposition. Skin samples from tamoxifen-injected untreated mice con-
tained approximately 1.5 fold greater hydroxyproline than control animals (Fig 2A). Bosutinib
treatment resulted in a dose-dependent decrease in skin collagen content with collagen levels
in skin from 10 mg/kg/day Bosutinib-treated mice not significantly different from the levels in
control mice. Lung samples from tamoxifen-injected mice contained approximately 1.9 fold
greater hydroxyproline than lungs from control mice (Fig 2B). Bosutinib treatment resulted in
a dose-dependent decrease in lung collagen content with the collagen levels in lung from 10
mg/kg/day Bosutinib-treated mice slightly but not significantly elevated compared to the levels
in control mice.
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Bosutinib abrogates the increased expression of genes encoding ECM
macromolecules and myofibroblast differentiation proteins in tamoxifen-
treated TBRIca-Col1a2-Cre skin and lungs
Changes in expression of genes encoding relevant ECM and profibrotic proteins in the skin
and lungs of mice with constitutive TGF-β fibroblast signaling compared to saline-treated con-
trol mice were assessed by quantitative RT-PCR. Expression levels of the genes encoding
Fig 1. Histopathology of skin and lung from control, tamoxifen-injected untreated and tamoxifen-injected
Bosutinib-treated TBRIca-Col1a2-Cre transgenic mice. A. Skin. Skin sections from saline-treated tamoxifen-injected
TBRIca-Col1a2-Cre mice demonstrate increased dermal thickness and perivascular collagen accumulation
(magnification 10X, second left panel) compared to skin sections from saline-treated non-tamoxifen-injected control
mice (upper left panel). Skin sections from animals treated by subdermal osmotic pumps releasing 2.5 mg/kg/day, 5.0
mg/kg/day or 10 mg/kg/day of Bosutinib (left panels) display dose-dependent decreases in collagen deposition and
dermal thickness compared with untreated mice. B. Lung. Sections from lung from saline-treated TBRIca-Col1a2-Cre
tamoxifen-injected mice (magnification 10X, second left panel) demonstrate marked loss of alveolar morphology with
tissue consolidation and thickening of alveolar septae and perivascular and interstitial collagen accumulation compared
to lung sections from saline-treated non-tamoxifen-injected control mice (upper left panel). Lung sections from
animals treated by subdermal osmotic pumps releasing 2.5 mg/kg/day, 5.0 mg/kg/day or 10 mg/kg/day of Bosutinib
(left panels) display a dose-dependent partial restoration of alveolar morphology and decreased thickening of alveolar
septae and perivascular and interstitial collagen accumulation compared with the untreated mice.
https://doi.org/10.1371/journal.pone.0196559.g001
Fig 2. Hydroxyproline content of skin and lungs from control, tamoxifen-injected untreated and tamoxifen-injected Bosutinib-
treated TBRIca-Col1a2-Cre transgenic mice. A portion of skin (A) or lung (B) isolated from animals in each treatment group (n = 6)
was hydrolyzed and analyzed for hydroxyproline content. The results were converted to total collagen tissue content and are expressed
as μg/mg of tissue wet weight. The bars show the mean +/- standard error of each treatment group performed in triplicate. Significance
determined by Student’s two-tailed t test. : p<0.05, : p<0.01, : p<0.001.
https://doi.org/10.1371/journal.pone.0196559.g002
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Col1a1 and Col3a1 were upregulated in the skin by an average of 2.8 fold and 4.2 fold (Fig 3A),
respectively and in the lungs by 2.5 fold and 2.4 fold, respectively, compared to tamoxifen-
injected untreated mice (Fig 3B). Fn1 expression was increased by 2.2 fold in the skin (Fig 3A)
and by 4.8 fold in the lungs (Fig 3B) of tamoxifen-injected mice whereas the fibrosis-associated
splice variant Fn-Eda displayed 5.5 fold and 2.5 fold increased expression in the skin and lung,
respectively, compared to control animals. Acta2/α-Sma expression was increased 4 fold in the
skin (Fig 3A) and 3.4 fold in the lung (Fig 3B) compared to saline injected animals whereas
the levels of the growth factor Ctgf/Ccn2were increased 2.6 and 3.0 fold in the skin and lung,
respectively. Bosutinib treatment produced a marked and dose-dependent decrease in the
expression of all these genes in both skin and lung with the levels measured in 10 mg/kg/day
Bosutinib-treated mice only slightly elevated compared to control untreated mice.
Effect of Bosutinib on the increased Tgfb1 expression and of genes
encoding TGF-β1 pathway components in tamoxifen-treated TBRIca-
Col1a2-Cre skin and lungs
Profibrotic growth factor Tgfb1expression levels were upregulated by 3.4 fold in the skin and
by 3.9 fold in the lungs of tamoxifen-injected animals compared to control animals and
Fig 3. Expression of genes encoding ECM components in the skin and lungs from control, tamoxifen-injected untreated and
tamoxifen-injected Bosutinib-treated TBRIca-Col1a2-Cre transgenic mice. Expression of Col1a1, Col3a1, Fn1, and Fn-Eda in
skin (A) and lung (B). The values shown are the mean (+/- SD) fold change levels of gene expression from each treatment group
(n = 6) performed in triplicate for each tissue. Expression levels were normalized to 18S levels and the expression levels in untreated
controls. Values for other samples are expressed relative to the normalized control. Significance was determined by Student’s T-test.
Statistical significance: : p<0.05, : p<0.01, : p<0.001.
https://doi.org/10.1371/journal.pone.0196559.g003
Bosutinib abrogates TGF-β-induced fibrosis in vivo
PLOS ONE | https://doi.org/10.1371/journal.pone.0196559 May 2, 2018 9 / 17
expression of its receptor Tgfbr1was upregulated 4 fold in the skin (Fig 4A) and 5.2 fold in the
lung (Fig 4B), reflecting tamoxifen-induced transgene expression and the subsequent para-
crine upregulation of TGF-β1 expression. Expression of the TGF-β-induced gene Comp was
upregulated in the skin and lungs of tamoxifen-injected mice by 2.7 fold and 3.0 fold respec-
tively (Fig 5A and 5B) and these increases were abrogated by Bosutinib. Bosutinib treatment
of the mice induced a dose-dependent decrease in expression of these genes however, even at
the 10 mg/kg/day dose, their expression remained significantly elevated compared to control
untreated mice.
Bosutinib abrogates the increased expression of genes encoding Erk1/2
protein kinases and Hic5
Expression levels of the TGF-β- and Src kinase-regulated Erk1 and Erk2 and of the TGF-β-
induced Hic5 gene were also examined. Erk1 levels were upregulated by 2.8 fold in the skin
and by 1.8 fold in the lungs of tamoxifen-injected mice compared to control mice and expres-
sion of the Erk2 kinase was upregulated 2.6 fold and 2.8 fold in the skin and lungs, respectively.
Hic5 expression levels increased 3.6 fold in the skin and 2.6 fold in the lungs of tamoxifen-
Fig 4. Expression of genes associated with myofibroblast transdifferentiation and with TGF-β signaling in the skin and lungs
from control, tamoxifen-injected untreated and tamoxifen-injected Bosutinib-treated TBRIca-Col1a2-Cre transgenic mice.
Expression of Acta2/Sma, Ctgf/Ccn2, Tgfb1, and Tgfbr1 in skin (A) and lung (B). The values shown are the mean (+/- SD) fold
change levels of gene expression from each treatment group (n = 6) performed in triplicate for each tissue. Expression levels were
normalized to 18S levels and the expression levels in untreated controls. Values for other samples are expressed relative to the
normalized control. Significance was determined by Student’s T-test. Statistical significance: : p<0.05, : p<0.01, : p<0.001.
https://doi.org/10.1371/journal.pone.0196559.g004
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injected mice (Fig 5A and 5B). Bosutinib treatment induced a dose-dependent decrease in
expression of these genes, and these levels were not significantly different in the 10 mg/kg/day
treated mice from those measured in the skin and lungs of saline-treated control animals.
Discussion
The effect of Bosutinib on the expression of genes encoding ECM components, regulation of
myofibroblast transdifferentiation and TGF-β1 production was previously examined in vitro
in SSc dermal fibroblasts [77]. Bosutinib induced a potent and dose-related inhibition of
COL1A2, COL3A1, FN1 and CTGF expression in SSc dermal fibroblasts and potent inhibition
of total collagen production by these cells. Intriguingly, the effect of Bosutinib on total collagen
production was highly selective for SSc dermal fibroblasts since only minimal effects on nor-
mal fibroblasts were observed. Importantly, Bosutinib also mediated a significant reduction in
the levels of α-SMA, a marker of myofibroblast activation of SSc fibroblasts [77]. The results of
these in vitro studies suggested that Bosutinib may represent a novel, selective and effective
antifibrotic agent for SSc therapy. The present study was performed to further validate this
suggestion in an in vivo animal model of tissue fibrosis. Bosutinib was tested in vivo employing
a highly relevant murine model of tissue fibrosis that possesses a fibroblast-specific tamoxifen-
Fig 5. Expression of the TBF-β target genes Comp and Erk1, Erk2 and the TGF-β-inducible Hic5 gene in the skin and lungs
from control, tamoxifen-injected untreated and tamoxifen-injected Bosutinib-treated TBRIca-Col1a2-Cre transgenic mice.
Expression of Comp, Erk1, Erk2, and Hic5 in skin (A) and lung (B). The values shown are the mean (+/- SD) fold change levels of
gene expression from each treatment group (n = 6) performed in triplicate for each tissue. Expression levels were normalized to 18S
levels and the expression levels in untreated controls. Values for other samples are expressed relative to the normalized control.
Significance was determined by Student’s T-test. Statistical significance: : p<0.05, : p<0.01, : p<0.001.
https://doi.org/10.1371/journal.pone.0196559.g005
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inducible constitutively active TGF-β receptor (TBRI) under control of the fibroblast-specific
Col1A2 gene [78,79]. This model reproduces more accurately the effects of upregulated TGF-β
signaling that has been associated with the establishment of a persistent profibrotic phenotype
in SSc [86,87].
Following tamoxifen-induced transgene expression activation, three doses (2.5, 5.0 or 10.0
mg/kg/day) of Bosutinib were administered to the TBRIca-Col1a2-Cre mice employing subder-
mal osmotic pumps that provide continuous release of Bosutinib over 42 days. Bosutinib
effects on the development of tissue fibrosis in skin and lungs were assessed by: 1) immunohis-
tochemistry; 2) measurement of tissue collagen content; 3) changes in the expression of genes
encoding various ECM components; and 4) assessment of the transdifferentiation of fibro-
blasts to profibrotic activated myofibroblasts. Bosutinib administration resulted in a marked
and dose-dependent decrease in skin and lung tissue fibrosis assessed by histopathologic anal-
ysis using Masson’s trichrome stain. In the skin, constitutive TGF-β signaling induced the
expected increase in collagen deposition and dermal thickness whereas Bosutinib-treated ani-
mals displayed decreased collagen deposition and dermal thicknesses compared with the
saline-treated animals. In the lung, constitutive TGF-β signaling induced dramatic tissue con-
solidation and alveolar thickening with abnormal and exaggerated perivascular and interstitial
collagen deposition, whereas in Bosutinib-treated mice a striking restoration or improvement
of tissue architecture and decreased collagen deposition was noted. These observations were
confirmed by the analysis of collagen deposition in the skin and lungs by measurement of
hydroxyproline levels. In both skin and lung, Bosutinib induced dose-dependent decreases in
hydroxyproline levels compared to control non-Bosutinib treated animals.
An analysis of profibrotic gene expression levels in response to Bosutinib revealed its effect
on multiple genes involved in the activation of myofibroblasts and encoding components of
the extracellular matrix that are regulated by TGF-β signaling. Col1a1, Col3a1, and Fn1 gene
expression increased following activation of TGF-β signaling in fibroblasts as did the expres-
sion of the fibrosis-specific splice variant Fn-Eda. Bosutinib decreased expression of these
genes in a dose-dependent manner, returning their expression levels to near the levels mea-
sured in non-tamoxifen control animals. A similar effect was observed on Acta2/Sma gene,
and on expression of genes encoding the TGF-β-induced proteins Comp and Hic5 and of the
TGF-β-regulated growth factor Ctgf/Ccn2. Expression of Tgfbr1, the receptor encoded by the
transgene was upregulated in tamoxifen-treated mice as was expression of Tgfb1. Bosutinib
reduced expression of these genes in a dose-dependent manner although they remained ele-
vated even at the 10 mg/kg/day dose most likely owing to the high level of transgene expres-
sion. The ability of Bosutinib to modify the TGF-β-mediated autocrine increased levels of
TGF-β and of the TGF-β receptors may represent one mechanism for the antifibrotic effects
that we observed in this model, however, since the levels of these genes remain upregulated
compared to the levels measured in control animals, the available evidence indicates that the
effects of Bosutinib on TGF-β-mediated skin and lung fibrosis are due to its suppression of the
ability of Src/c-Abl kinases to mediate the downstream effects of TGF-β signaling. Finally, the
expression levels of the genes encoding Erk1 and Erk2 kinases that were significantly upregu-
lated following activation of constitutive TGF-β signaling were reduced in a dose-dependent
manner following Bosutinib treatment.
In conclusion, Bosutinib displays potent anti-fibrotic effects in an in vivo model of TGF-β-
mediated tissue fibrosis, reducing the development of fibrosis in the skin and lungs of treated
animals in a dose-dependent manner as assessed by histopathologic analysis of collagen depo-
sition, by measurement of the levels of hydroxyproline as a biochemical analysis of total colla-
gen content in the isolated skin and lungs of these animals, and by the analysis of the
expression of genes encoding ECM components, markers of myofibroblast activation and
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differentiation, and of relevant profibrotic kinases and other TGF-β1 molecular targets. The
results obtained therefore extend the observations of the previously reported in vitro study of
the antifibrotic effects of Bosutinib in SSc dermal fibroblasts [40] to an in vivo transgenic
mouse model of TGF-β-mediated tissue fibrosis and overall reinforce the previously stated
conclusion that Bosutinib [77] may represent a novel, selective and effective antifibrotic agent
for therapy of SSc and other fibrotic disorders.
Acknowledgments
The expert assistance of Alana Pagano in the preparation of this manuscript is greatly
acknowledged.
Author Contributions
Conceptualization: Peter J. Wermuth, Sergio A. Jimenez.
Formal analysis: Peter J. Wermuth.
Funding acquisition: Sergio A. Jimenez.
Investigation: Peter J. Wermuth.
Methodology: Peter J. Wermuth.
Project administration: Sergio A. Jimenez.
Resources: Sergio A. Jimenez.
Supervision: Sergio A. Jimenez.
Validation: Peter J. Wermuth.
Writing – original draft: Peter J. Wermuth.
Writing – review & editing: Peter J. Wermuth, Sergio A. Jimenez.
References
1. Rosenbloom J, Macarak E, Piera-Velazquez S, Jimenez SA. Human fibrotic diseases: current chal-
lenges in fibrosis research. Meth Mol Biol. 2017; 1627: 1–23.
2. Rosenbloom J, Mendoza FA, Jimenez SA. Strategies for Antifibrotic Therapies. Biochim Biophys Acta.
2013; 1832: 1088–1103. https://doi.org/10.1016/j.bbadis.2012.12.007 PMID: 23266403
3. Rosenbloom J, Castro SV, Jimenez SA. Narrative review: fibrotic diseases: cellular and molecular
mechanisms and novel therapies. Ann Intern Med. 2010; 152: 159–166. https://doi.org/10.7326/0003-
4819-152-3-201002020-00007 PMID: 20124232
4. Denton CP, Khanna D. Systemic sclerosis. Lancet. 2017; 390: 1685–1699. https://doi.org/10.1016/
S0140-6736(17)30933-9 PMID: 28413064
5. Varga J, Abraham D. Systemic sclerosis: a prototypic multisystem fibrotic disorder. J Clin Invest. 2007;
117: 557–567. https://doi.org/10.1172/JCI31139 PMID: 17332883
6. Mendoza FA, Artlett CM, Sandorfi N, Latinis K, Piera-Velazquez S, Jimenez SA. Description of 12
cases of Nephrogenic Fibrosing Dermopathy and review of the literature. Semin Arthritis Rheum. 2006;
35: 238–249. https://doi.org/10.1016/j.semarthrit.2005.08.002 PMID: 16461069
7. Noble PW, Barkauskas CE, Jiang D. Pulmonary fibrosis: patterns and perpetrators. J Clin Invest. 2012;
122: 2756–2762. https://doi.org/10.1172/JCI60323 PMID: 22850886
8. Wynn TA. Common and unique mechanisms regulate fibrosis in various fibroproliferative diseases. J
Clin Invest. 2007; 117: 524–529. https://doi.org/10.1172/JCI31487 PMID: 17332879
9. Jimenez SA, Castro SV, Piera-Velazquez M. Role of growth factors in the pathogenesis of tissue fibro-
sis in Systemic Sclerosis. Curr Rheumatol Rev. 2010; 6: 283–294. PMID: 25693043
Bosutinib abrogates TGF-β-induced fibrosis in vivo
PLOS ONE | https://doi.org/10.1371/journal.pone.0196559 May 2, 2018 13 / 17
10. Zeisberg M, Kalluri R. Cellular mechanisms of tissue fibrosis. 1. Common and organ-specific mecha-
nisms associated with tissue fibrosis. Am J Physiol Cell Physiol. 2013; 304: C216–C225. https://doi.org/
10.1152/ajpcell.00328.2012 PMID: 23255577
11. Rockey DC, Bell PD, Hill JA. Fibrosis-a common pathway to organ injury and failure. N Engl J Med.
2015; 372: 1138–1149. https://doi.org/10.1056/NEJMra1300575 PMID: 25785971
12. Hinz B, Phan SH, Thannickal VJ, Galli A, Bochaton-Piallat ML, Gabbiani G. The myofibroblast: one
function, multiple origins. Am J Pathol. 2007; 170: 1807–1816. https://doi.org/10.2353/ajpath.2007.
070112 PMID: 17525249
13. McAnulty RJ. Fibroblasts and myofibroblasts: their source, function and role in disease. Int J Biochem
Cell Biol. 2007; 39: 666–671. https://doi.org/10.1016/j.biocel.2006.11.005 PMID: 17196874
14. Hinz B, Phan SH, Thannickal VJ, Prunotto M, Desmoulière A, Varga J et al. Recent developments in
myofibroblast biology: paradigms for connective tissue remodeling. Am J Pathol. 2012; 180: 1340–
1355. https://doi.org/10.1016/j.ajpath.2012.02.004 PMID: 22387320
15. Falke LL, Gholizadeh S, Goldschmeding R, Kok RJ, Nguyen TQ. Diverse origins of the myofibroblast-
implications for kidney fibrosis. Nat Rev Nephrol. 2015; 11: 233–244. https://doi.org/10.1038/nrneph.
2014.246 PMID: 25584804
16. Varga J, Rosenbloom J, Jimenez SA. Transforming growth factor-β (TGFβ) causes a persistent
increase in steady state levels of Type I and Type III collagens and fibronectin mRNAs in normal human
dermal fibroblasts. Biochem J. 1987; 247: 597–604. PMID: 3501287
17. Lafyatis R. Transforming growth factor β—at the centre of systemic sclerosis. Nat Rev Rheumatol.
2014; 10: 706–719. https://doi.org/10.1038/nrrheum.2014.137 PMID: 25136781
18. Carthy JM. TGFβ signaling and the control of myofibroblast differentiation: Implications for chronic
inflammatory disorders. J Cell Physiol. 2017; 429: 2373–2386.
19. Trojanowska M. Role of PDGF in fibrotic diseases and systemic sclerosis. Rheumatology (Oxford).
2008; 47 Suppl 5: v2–4.
20. Varga J, Whitfield ML. Transforming growth factor-beta in systemic sclerosis (scleroderma). Front
Biosci (Schol Ed). 2009; 1: 226–235.
21. Yamashita H, ten Dijke P, Franzen P, Miyazono K, Heldin CH. Formation of hetero-oligomeric com-
plexes of type I and type II receptors for transforming growth factor-beta. J Biol Chem. 1994; 269:
20172–20178. PMID: 8051105
22. Wrana JL, Attisano L, Wieser R, Ventura F, Massague J. Mechanism of activation of the TGF-beta
receptor. Nature. 1994; 370: 341–347. https://doi.org/10.1038/370341a0 PMID: 8047140
23. Dennler S, Itoh S, Vivien D, ten Dijke P, Huet S, Gauthier JM. Direct binding of Smad3 and Smad4 to
critical TGF beta-inducible elements in the promoter of human plasminogen activator inhibitor-type 1
gene. EMBO J. 1998; 17: 3091–3100. https://doi.org/10.1093/emboj/17.11.3091 PMID: 9606191
24. Kawabata M, Inoue H, Hanyu A, Imamura T, Miyazono K. Smad proteins exist as monomers in vivo and
undergo homo- and hetero-oligomerization upon activation by serine/threonine kinase receptors.
EMBO J. 1998; 17: 4056–4065. https://doi.org/10.1093/emboj/17.14.4056 PMID: 9670020
25. Derynck R, Zhang Y, Feng XH. Smads: transcriptional activators of TGF-beta responses. Cell. 1998;
95: 737–740. PMID: 9865691
26. Inman GJ, Nicolas FJ, Hill CS. Nucleocytoplasmic shuttling of Smads 2, 3, and 4 permits sensing of
TGF-beta receptor activity. Mol Cell. 2002; 10: 283–294. PMID: 12191474
27. Perlman R, Schiemann WP, Brooks MW, Lodish HF, Weinberg RA. TGF-beta-induced apoptosis is
mediated by the adapter protein Daxx that facilitates JNK activation. Nat Cell Biol. 2001; 3: 708–714.
https://doi.org/10.1038/35087019 PMID: 11483955
28. Zhang L, Wang W, Hayashi Y, Jester JV, Birk DE, Gao M, et al. A role for MEK kinase 1 in TGF-beta/
activing-induced epithelium movement and embryonic eyelid closure. EMBO J. 2003; 22: 4443–4454.
https://doi.org/10.1093/emboj/cdg440 PMID: 12941696
29. Bhowmick NA, Ghiassi M, Bakin A, Aakre M, Lundquist CA, Engel ME, et al. Transforming growth fac-
tor-beta 1 mediates epithelial to mesenchymal transdifferentiation through a RhoA-dependent mecha-
nism. Mol Cell Biol. 2001; 12: 27–36.
30. Ihn H, Yamane K, Kubo M, Tamaki K. Blockade of endogenous transforming growth factor β signaling
prevents up-regulated collagen synthesis in scleroderma fibroblasts: Association with increased
expression of transforming growth factor β receptors. Arthritis Rheum. 2001; 44: 474–480. https://doi.
org/10.1002/1529-0131(200102)44:2<474::AID-ANR67>3.0.CO;2-# PMID: 11229480
31. Kawakami T, Ihn H, Xu W, Smith E, LeRoy C, Trojanowska M. Increased expression of TGF-beta
receptors by scleroderma fibroblasts: evidence for contribution of autocrine TGF-beta signaling to
scleroderma phenotype. J Invest Dermatol. 1998; 110: 47–51. https://doi.org/10.1046/j.1523-1747.
1998.00073.x PMID: 9424086
Bosutinib abrogates TGF-β-induced fibrosis in vivo
PLOS ONE | https://doi.org/10.1371/journal.pone.0196559 May 2, 2018 14 / 17
32. Leask A, Abraham DJ, Finlay DR, Holmes A, Pennington D, Shi-Wen X, et al. Dysregulation of trans-
forming growth factor beta signaling in scleroderma: overexpression of endoglin in cutaneous sclero-
derma fibroblasts. Arthritis Rheum. 2002; 46: 1857–1865. https://doi.org/10.1002/art.10333 PMID:
12124870
33. Holmes A, Abraham DJ, Sa S, Shiwen X, Black CM, Leask A. CTGF and SMADs, maintenance of
scleroderma phenotype is independent of SMAD signaling. J Biol Chem. 2001; 276: 10594–10601.
https://doi.org/10.1074/jbc.M010149200 PMID: 11152469
34. Leask A, Sa S, Holmes A, Shiwen X, Black CM, Abraham DJ. The control of ccn2 (ctgf) gene expression
in normal and scleroderma fibroblasts. Mol Pathol. 2001; 54: 180–183. PMID: 11376132
35. Pannu J, Nakerakanti S, Smith E, ten Dijke P, Trojanowska M. Transforming growth factor-beta recep-
tor type I-dependent fibrogenic gene program is mediated via activation of Smad1 and ERK1/2 path-
ways. J Biol Chem. 2007; 282: 10405–10413. https://doi.org/10.1074/jbc.M611742200 PMID:
17317656
36. Mori Y, Chen SJ, Varga J. Expression and regulation of intracellular SMAD signaling in scleroderma
skin fibroblasts. Arthritis Rheum. 2003; 48: 1964–1978. https://doi.org/10.1002/art.11157 PMID:
12847691
37. Lakos G, Takegawa S, Chen SJ, Ferreira AM, Han G, Masuda K, et al. Targeted disruption of TGF-
beta/Smad3 signaling modulates skin fibrosis in a mouse model of scleroderma. Am J Pathol. 2004;
165: 203–217. PMID: 15215176
38. Jinnin M, Ihn H, Tamaki K. Characterization of SIS3, a novel specific inhibitor of Smad3, and its effect
on transforming growth factor-beta1-induced extracellular matrix expression. Mol Pharmacol. 2006; 69:
597–607. https://doi.org/10.1124/mol.105.017483 PMID: 16288083
39. Laping NJ, Grygielko E, Mathur A, Butter S, Bomberger J, Tweed C, et al. Inhibition of transforming
growth factor (TGF)-beta1-induced extracellular matrix with a novel inhibitor of the TGF-beta type I
receptor kinase activity: SB-431542. Mol Pharmacol. 2002; 62: 58–64. PMID: 12065755
40. Beyer C, Zenzmaier C, Palumbo-Zerr K, Mancuso R, Distler A, Dees C, et al. Stimulation of the soluble
guanylate cyclase (sGC) inhibits fibrosis by blocking non-canonical TGFβ signaling. Ann Rheum Dis.
2015; 74: 1408–1416. https://doi.org/10.1136/annrheumdis-2013-204508 PMID: 24567525
41. Sato M, Shegogue D, Gore EA, McDermott PJ, Trojanowska M. Role of p38 MAPK in transforming
growth factor beta stimulation of collagen production by scleroderma and healthy dermal fibroblasts. J
Invest Dermatol 2002; 118:704–711. https://doi.org/10.1046/j.1523-1747.2002.01719.x PMID:
11918720
42. Denton CP, et al. Recombinant human anti-transforming growth factor beta1 antibody therapy in sys-
temic sclerosis: a multicenter, randomized, placebo-controlled phase I/II trial of CAT-192. Arthritis
Rheum. 2007; 56: 323–333. https://doi.org/10.1002/art.22289 PMID: 17195236
43. CAT-152 0102 Trabeculectomy Study Group, Khaw P, Grehn F, Hollo G, Overton B, Wilson R, et al. A
phase III study of subconjunctival human anti-transforming growth factor beta(2) monoclonal antibody
(CAT-152) to prevent scarring after first time trabeculectomy. Ophthalmology. 2007; 114: 1822–1830.
https://doi.org/10.1016/j.ophtha.2007.03.050 PMID: 17908591
44. Rice LM, Merkel PA, Furst DE, Khanna D, Emery P, Hsu VM, et al. Fresolimumab treatment decreases
biomarkers and improves clinical symptoms in systemic sclerosis patients. J Clin Invest. 2015; 125:
2795–2807. https://doi.org/10.1172/JCI77958 PMID: 26098215
45. Skhirtladze C, Distler O, Dees C, Akhmetshina A, Busch N, Venalis P et al. Src kinases in systemic scle-
rosis: central roles in fibroblast activation and in skin fibrosis. Arthritis Rheum. 2008; 58: 1475–1484.
https://doi.org/10.1002/art.23436 PMID: 18438865
46. Mendoza FA, Jimenez SA. Tyrosine kinase inhibitor therapy for systemic sclerosis: Quo vadis? Arthritis
Rheum. 2011; 63: 3199–3203. https://doi.org/10.1002/art.30545 PMID: 21769846
47. Gordon JK, Spiera LF. Targeting tyrosine kinases: a novel therapeutic strategy for systemic sclerosis.
Curr Opin Rheumatol. 2010; 22: 690–695. https://doi.org/10.1097/BOR.0b013e32833f1105 PMID:
20827202
48. Distler JH, Distler O. Intracellular tyrosine kinases as novel targets for anti-fibrotic therapy in systemic
sclerosis. Rheumatology (Oxford). 2008; 47 Suppl 5: v10–11.
49. Lowell CA. Src-family kinases: rheostats of immune cell signaling. Mol Immunol. 2004; 41: 631–643.
https://doi.org/10.1016/j.molimm.2004.04.010 PMID: 15220000
50. Okutani D, Lodyga M, Han B, Liu M. Src protein tyrosine kinase family and acute inflammatory
responses. Am J Physiol Lung Cell Mol Physiol. 2006; 291: L129–L141. https://doi.org/10.1152/ajplung.
00261.2005 PMID: 16581827
Bosutinib abrogates TGF-β-induced fibrosis in vivo
PLOS ONE | https://doi.org/10.1371/journal.pone.0196559 May 2, 2018 15 / 17
51. Catarzi S, Biagioni C, Giannoni E, Favilli F, Marcucci T, Iantomasi T, et al. Redox regulation of platelet-
derived growth-factor-receptor: role of NADPH-oxidase and c-Src tyrosine kinase. Biochim Biophys
Acta. 2005: 1745: 166–175. https://doi.org/10.1016/j.bbamcr.2005.03.004 PMID: 16129124
52. Mishra R, Zhu L, Eckert RL, Simonson MS. TGF-beta-regulated collagen type I accumulation: role of
Src-based signals. Am J Physiol Cell Physiol. 2007; 292: C1361–C1369. https://doi.org/10.1152/
ajpcell.00370.2006 PMID: 17135298
53. Thannickal VJ, Lee DY, White ES, Cui Z, Larios JM, Chacon R, et al. Myofibroblast differentiation by
transforming growth factor-beta 1 is dependent on cell adhesion and integrin signaling via focal adhe-
sion kinase. J Biol Chem. 2003; 278: 12384–12389. https://doi.org/10.1074/jbc.M208544200 PMID:
12531888
54. Dabiri G, Tumbarello DA, Turner CE, Van de Water L. TGF-beta1 slows the growth of pathogenic myofi-
broblasts through a mechanism requiring the focal adhesion protein, Hic-5. J Invest Dermatol. 2008;
128: 280–291. https://doi.org/10.1038/sj.jid.5700975 PMID: 17671518
55. Varney SD, Betts CB, Zheng R, Wu L, Hinz B, Zhou J, et al. Hic5 is required for myofibroblast differenti-
ation by regulating mechanically dependent MRTF-A nuclear accumulation. J Cell Sci. 2016; 129: 774–
787. https://doi.org/10.1242/jcs.170589 PMID: 26759173
56. Haak AJ, Tsou PS, Amin MA, Ruth JH, Campbell P, Fox DA, et al. Targeting the myofibroblast genetic
switch: inhibitors of myocardin-related transcription factor/serum response factor-regulated gene tran-
scription prevent fibrosis in a murine model of skin injury. J Pharmacol Exp Ther. 2014; 349: 480–486.
https://doi.org/10.1124/jpet.114.213520 PMID: 24706986
57. Shiwen X, Stratton R, Nikitorowicz-Buniak J, Ahmed-Abdi B, Ponticos M, Denton C, et al. A role of myo-
cardin-related transcription factor-A (MRTF-A) in scleroderma related fibrosis. PLoS One. 2015; 10:
e0126015. https://doi.org/10.1371/journal.pone.0126015 PMID: 25955164
58. Shi-wen X, Thompson K, Khan K, Liu S, Murphy-Marshman H, Baron M, et al. Focal adhesion kinase
and reactive oxygen species contribute to the persistent fibrotic phenotype of lesional scleroderma fibro-
blast. Rheumatology (Oxford). 2012; 51: 2146–2154.
59. Mimura Y, Ihn H, Jinnin M, Asano Y, Yamane K, Tamaki K. Constitutive phosphorylation of focal adhe-
sion kinase is involved in the myofibroblast differentiation of scleroderma fibroblasts. J Invest Dermatol.
2005; 124: 886–892. https://doi.org/10.1111/j.0022-202X.2005.23701.x PMID: 15854026
60. Distler JH, Jungel A, Humber LC, Schulze-Horsel U, Zwerina J, Gay RE, et al. Imatinib mesylate
reduces production of extracellular matrix and prevents development of experimental dermal fibrosis.
Arthritis Rheum. 2007; 56: 311–322. https://doi.org/10.1002/art.22314 PMID: 17195235
61. Bhattacharyya S, Ishida W, Wu M, Wilkes M, Mori Y, Hinchcliff M, et al. A non-Smad mechanism of
fibroblast activation by transforming growth factor-beta via c-Abl and Egr-1: selective modulation by
imatinib mesylate. Oncogene. 2009; 28: 1285–1297. https://doi.org/10.1038/onc.2008.479 PMID:
19151753
62. Horton JA, Chung EJ, Hudak KE, Sowers A, Thetford A, White AO, et al. Inhibition of radiation-induced
skin fibrosis with imatinib. Int J Radiat Biol. 2013; 89: 162–170. https://doi.org/10.3109/09553002.2013.
741281 PMID: 23083077
63. Daniels CE, Wilkes MC, Edens M, Kottom TJ, Murphy SJ, Limper AH, et al. Imatinib mesylate inhibits
the profibrogenic activity of TGF-beta and prevents bleomycin-mediated lung fibrosis. J Clin Invest.
2004; 114: 1308–1316. https://doi.org/10.1172/JCI19603 PMID: 15520863
64. Wang S, Wilkes MC, Leof EB, Hirschberg R. Imatinib mesylate blocks a non-Smad TGF-beta pathway
and reduces renal fibrogenesis in vivo. FASEB J. 2005; 19: 1–11. https://doi.org/10.1096/fj.04-
2370com PMID: 15629889
65. Sabnani I, Zucker MJ, Rosenstein ED, Baran DA, Arroyo LH, Tsang P, et al. A novel therapeutic
approach to the treatment of scleroderma-associated pulmonary complications: safety and efficacy of
combination therapy with imatinib and cyclophosphamide. Rheumatology (Oxford). 2009; 48: 49–52.
66. Sfikakis PP, Gorgoulis VG, Katsiari CG, Evangelou K, Kostopoulos C, Black CM. Imatinib for the treat-
ment of refractory, diffuse systemic sclerosis. Rheumatology (Oxford). 2008; 47: 735–737.
67. Distler JH, Manger B, Spriewald BM, Schett G, Distler O. Treatment of pulmonary fibrosis for twenty
weeks with imatinib mesylate in a patient with mixed connective tissue disease. Arthritis Rheum. 2008;
58: 2538–2542. https://doi.org/10.1002/art.23694 PMID: 18668536
68. Kay J, High WA. Imatinib mesylate treatment of nephrogenic systemic fibrosis. Arthritis Rheum. 2008;
58: 2543–2548. https://doi.org/10.1002/art.23696 PMID: 18668587
69. Daniels CE, Lasky JA, Limper AH, Mieras K, Gabor E, Schroeder DR, et al. Imatinib treatment for idio-
pathic pulmonary fibrosis: Randomized placebo-controlled trial results. Am J Respir Crit Care Med.
2010; 181: 604–610. https://doi.org/10.1164/rccm.200906-0964OC PMID: 20007927
Bosutinib abrogates TGF-β-induced fibrosis in vivo
PLOS ONE | https://doi.org/10.1371/journal.pone.0196559 May 2, 2018 16 / 17
70. Akhmetshina A, et al., Dual inhibition of c-abl and PDGF receptor signaling by dasatinib and nilotinib for
the treatment of dermal fibrosis. FASEB J 2008; 22:2214–2222. https://doi.org/10.1096/fj.07-105627
PMID: 18326784
71. Golas JM, Arndt K, Etienne C, Lucas J, Nardin D, Gibbons J, et al. SKI-606, a 4-anilo-3-quinolinecarbo-
nitrile dual inhibitor of Src and Abl kinases, is a potent antiproliferative agent against chronic myeloge-
nous leukemia cells in culture and causes regression of K562 xenografts in nude mice. Cancer Res.
2003; 63: 375–381. PMID: 12543790
72. Puttini M, Coluccia AM, Boschelli F, Cleris L, Marchesi E, Donella-Deana A, et al. In vitro and in vivo
activity of SKI-606, a novel Src-Abl inhibitor, against imatinib-resistant Bcr-Abl+ neoplastic cells. Cancer
Res. 2006; 66: 11314–11322. https://doi.org/10.1158/0008-5472.CAN-06-1199 PMID: 17114238
73. Keller V, Amsberg G, Brummendorf TH. Novel aspects of therapy with the dual Src and Abl kinase inhib-
itor bosutinib in chronic myeloid leukemia. Expert Rev Anticancer Ther. 2012; 12: 1121–1127. https://
doi.org/10.1586/era.12.84 PMID: 23098112
74. Mathew P, Thall PF, Bucana CD, Oh WK, Morris MJ, Jones DM, et al. Platelet-derived growth factor
receptor inhibition and chemotherapy for castration-resistant prostate cancer with bone metastases.
Clin Cancer Res. 2007; 13: 5816–5824. https://doi.org/10.1158/1078-0432.CCR-07-1269 PMID:
17908974
75. Mathew P, Thall PF, Bucana CD, Jones D, Home E, Oh WK, et al. Dynamic change in phosphorylated
platelet-derived growth factor receptor in peripheral blood leukocytes following docetaxel therapy pre-
dicts progression-free and overall survival in prostate cancer. Br J Cancer. 2008; 99: 1426–1432.
https://doi.org/10.1038/sj.bjc.6604706 PMID: 18841158
76. Kantarjian HM, Cortes JE, Kim DW, Khoury HJ, Brummendorf TH, Porkka K, et al. Bosutinib safety and
management of toxicity in leukemia patients with resistance or intolerance to imatinib and other tyrosine
kinase inhibitors. Blood. 2014; 123: 1309–1318. https://doi.org/10.1182/blood-2013-07-513937 PMID:
24345751
77. Piera-Velazquez S., Fasino K., Jimenez S.A. Antifibrotic effects of the tyrosine kinase inhibitor, Bosuti-
nib, on cultured normal and Systemic Sclerosis dermal fibroblasts. Abstracts from the 4th Systemic
Sclerosis World Congress (Abstract Number P.020). Journal of Scleroderma and Related Disorders.
2016; 1: 48–49.
78. Sonnylal S, Denton CP, Zheng B, Keene DR, He R, Adams HP, et al. Postnatal induction of transform-
ing growth factor beta signaling in fibroblasts of mice recapitulates clinical, histologic, and biochemical
features of scleroderma. Arthritis Rheum. 2007; 56: 334–344. https://doi.org/10.1002/art.22328 PMID:
17195237
79. Derrett-Smith EC, Denton CP, Sonnylal S. Animal models of scleroderma: lessons from transgenic and
knockout mice. Curr Opin Rheumatol. 2009; 21: 630–635. https://doi.org/10.1097/BOR.
0b013e32833130c1 PMID: 19730378
80. Markova MS, Zeskand J, McEntee B, Rothstein J, Jimenez SA, Siracusa LD. A role for the androgen
receptor in collagen content of the skin. J Invest Dermatol. 2004; 123: 1052–1056. https://doi.org/10.
1111/j.0022-202X.2004.23494.x PMID: 15610513
81. Manne J, Markova M, Siracusa LD, Jimenez SA. Collagen content in skin and internal organs of the
tight skin mouse: an animal model of scleroderma. Biochem Res Int. 2013: 436053. https://doi.org/10.
1155/2013/436053 PMID: 24260716
82. Stegemann H, Stalder K. Determination of hydroxyproline. Clin Chim Acta. 1967; 18: 267–273. PMID:
4864804
83. Edwards CA, O’Brien WD Jr. Modified assay for determination of hydroxyproline in a tissue hydrolysate.
Clin Chim Acta. 1980; 104: 161–167. PMID: 7389130
84. Wermuth PJ, Del Galdo F, Jimenez SA. Induction of the expression of profibrotic cytokines and growth
factors in normal human peripheral blood monocytes by gadolinium contrast agents. Arthritis Rheum.
2009; 60: 1508–1518. https://doi.org/10.1002/art.24471 PMID: 19404939
85. Mendoza FA, Piera-Velazquez S, Farber JL Feghali-Bostwick C, Jimenez SA. Endothelial cells
expressing endothelial and mesenchymal cell gene products in lung tissue from patients with systemic
sclerosis-associated interstitial lung disease. Arthritis Rheumatol. 2016; 68: 210–217. https://doi.org/
10.1002/art.39421 PMID: 26360820
86. Artlett CM. Animal models of systemic sclerosis: their utility and limitations. Open Access Rheumatol.
2014; 6: 65–81. https://doi.org/10.2147/OARRR.S50009 PMID: 27790036
87. Avouac J. Mouse model of experimental dermal fibrosis: the bleomycin-induced dermal fibrosis. Meth-
ods Mol Biol. 2014; 1142: 91–98. https://doi.org/10.1007/978-1-4939-0404-4_11 PMID: 24706279
Bosutinib abrogates TGF-β-induced fibrosis in vivo
PLOS ONE | https://doi.org/10.1371/journal.pone.0196559 May 2, 2018 17 / 17
